Tarsus Pharmaceuticals, Inc. TARS Operating Lease Liability Payments - 2026 (Lessee)
Operating Lease Liability Payments - 2026 (Lessee) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease liability payments - 2026 (lessee).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s operating lease liability payments - 2026 (lessee)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease liability payments - 2026 (lessee) of $2.78M in Q1 2026.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating lease liability payments - 2026 (lessee)?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating lease liability payments - 2026 (lessee) has grown at a 57.3% compound annual growth rate (CAGR), from $281K to $2.7M.
- What does operating lease liability payments - 2026 (lessee) mean?
- This represents the specific cash outflow commitment for operating leases scheduled for the calendar year 2026. It allows investors to isolate the impact of real estate and equipment lease obligations on the company's cash flow in a specific future period.